Amotz Nechushtan

Iluten Ltd. developed a novel anti-inflammatory drug for the treatment of inflammatory bowel disease. It was established under a strategic collaboration between Pontifax and Clal Biotechnology. The new drug, a monoclonal antibody that modulates the immune system, has shown promising good results both in vitro and in vivo (in IBD and Multiple sclerosis animal disease models). The company was founded by Dr. Amotz Nechushtan in 2010 and is headquartered in Ashkelon, Israel.

Cellect Biotechnology Ltd. engages in the provision of regenerative medicine. Its activities include development of regenerative medicine through the development of products facilitating immune stem cell selection. The company also develops innovative technology, which allows the default stem cells by dramatically reducing of complications existing in conventional selection methods. The company was founded by Kasbian Nuriel Chirich, Shai Yarkoni, and Nadir Askenasy on August 4, 1986 and is headquartered in Kfar Saba, Israel.

QuantomiX Ltd. develops and markets capsules that enable real-time analysis of wet cells and tissue biopsies. The firm with the its QXTM capsule product line, wet samples, including cells and tissues biopsies, will be able to be examined immediately and accurately. The company's technology enables scanning electron microscopes (SEM) to image and analyze wet samples such as cells, tissue biopsies, foods and ink, in their native environment. QuantomiX was founded in March 2001 by Micha Brunstein, Zachy Berger and Ory S. Zik and is headquartered in Rehovot, Israel.